PubRank

Jessica C Hassel

Author PubWeight™ 97.71‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010 67.34
2 Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 2012 11.72
3 Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2014 10.38
4 The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. Cancer Discov 2013 3.71
5 Radiopharmaceutical therapy of patients with metastasized melanoma with the melanin-binding benzamide 131I-BA52. J Nucl Med 2013 1.53
6 Predictive value of early 18F-FDG PET/CT studies for treatment response evaluation to ipilimumab in metastatic melanoma: preliminary results of an ongoing study. Eur J Nucl Med Mol Imaging 2014 0.98
7 Adenovirus-mediated intralesional interferon-gamma gene transfer induces tumor regressions in cutaneous lymphomas. Blood 2004 0.96
8 STAT5 contributes to interferon resistance of melanoma cells. Curr Biol 2005 0.96
9 Chemovirotherapy of malignant melanoma with a targeted and armed oncolytic measles virus. J Invest Dermatol 2012 0.88
10 Predicting tooth color from facial features and gender: results from a white elderly cohort. J Prosthet Dent 2008 0.83
11 Therapy response assessment in metastatic melanoma patients treated with a BRAF inhibitor: adapted Choi criteria can reflect early therapy response better than does RECIST. Acad Radiol 2013 0.80
12 Effectiveness and tolerability of ipilimumab: experiences from 198 patients included in a named-patient program in various daily-practice settings and multiple institutions. J Immunother 2014 0.79
13 18F-FDG PET/CT Reveals Disease Remission in a Patient With Ipilimumab-Refractory Advanced Melanoma Treated With Pembrolizumab. Clin Nucl Med 2016 0.78
14 Cutis verticis gyrata-like skin toxicity during treatment of melanoma patients with the BRAF inhibitor vemurafenib after whole-brain radiotherapy is a consequence of the development of multiple follicular cysts and milia. Strahlenther Onkol 2014 0.76
15 Histogram analysis of iodine maps from dual energy computed tomography for monitoring targeted therapy of melanoma patients. Future Oncol 2015 0.76
16 Vemurafenib therapy for stage IV melanoma with V600G-mutation. J Dtsch Dermatol Ges 2013 0.76
17 Immunotherapy of Melanoma. Oncol Res Treat 2016 0.76
18 Varicella-like cutaneous toxoplasmosis in a patient with aplastic anemia. J Clin Microbiol 2013 0.75
19 Metastatic melanoma response to combination therapy with ipilimumab and vemurafenib. Hell J Nucl Med 2017 0.75
20 Severe Ocular Myositis After Ipilimumab Treatment for Melanoma: A Report of 2 Cases. J Immunother 2017 0.75
21 [Multiple, flesh-coloured, firm, grouped papulonoduleson the right forehead]. J Dtsch Dermatol Ges 2011 0.75
22 Necrolytic migratory erythema in a patient with neuroendocrine carcinoma. Intern Med 2013 0.75
23 Liquid Biopsy: Value for Melanoma Therapy? Oncol Res Treat 2017 0.75
24 PD-1 Antibody-induced Guillain-Barré Syndrome in a Patient with Metastatic Melanoma. Acta Derm Venereol 2016 0.75
25 Escalating therapy of cutaneous side effects of EGFR inhibitors: experience of German reference centers. J Dtsch Dermatol Ges 2012 0.75
26 Axillary accessory breast tissue--case report and review of literature. J Dtsch Dermatol Ges 2014 0.75
27 Erosive and mitotically active juvenile xanthogranuloma on the neck of an infant. J Dtsch Dermatol Ges 2014 0.75
28 Safe Administration of An Anti-PD-1 Antibody to Kidney-transplant Patients: 2 Clinical Cases and Review of the Literature. J Immunother 2017 0.75
29 Reinduction of PD1-inhibitor therapy: first experience in eight patients with metastatic melanoma. Melanoma Res 2017 0.75